Accretion Pharmaceuticals Ltd Financials
Company Logo

Accretion Pharmaceuticals Ltd Financial Statement

Accretion Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Accretion Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual13.35
Operating Expenses Annual10.72
Operating Profit Annual2.69
Interest Annual0.47
Depreciation0.22
Net Profit Annual1.49
Tax Annual0.50

Accretion Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the BeginningTBA
Cash Flow from Operations-11.44
Cash Flow from Investing-5.48
Cash Flow from Financing17.01
Cash Flow at the End0.09

Accretion Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)20.15
PBIT Margin (%)18.50
PBT Margin (%)-20.68
Net PROFIT Margin (%)11.16
Return On Networth / Equity (%)65.14
Return On Networth /Employed (%)31.12
Return On Assets (%)18.86
Total Debt / Equity (X)2.46
Asset Turnover Ratio (%)1.69

Accretion Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual5.25
Total Current Assets Annual21.48
Non Current Assets Annual5.39
Total Shareholders Funds Annual5.49
Total Assets Annual26.87

Accretion Pharmaceuticals Ltd Earning Calls

No Data Availabe

FAQS on Accretion Pharmaceuticals Ltd Financials

As of May 22, 2025, Accretion Pharmaceuticals Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.

Yes, Accretion Pharmaceuticals Ltd is not with a debt-to-equity ratio of 2.52.

In FY 2024 , Accretion Pharmaceuticals Ltd recorded a total revenue of approximately 33.67 Cr marking a significant milestone in the company's financial performance.

Accretion Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and 0.2% annually, respectively..

Accretion Pharmaceuticals Ltd's current PE ratio is .

Accretion Pharmaceuticals Ltd's ROCE averaged 19.0% from the FY ending March 2022 to 2024, with a median of 10.5%. It peaked at 36.7% in March 2024, reflecting strong capital efficiency over the period..

Accretion Pharmaceuticals Ltd's latest EBIT is Rs. 6.91 Cr, surpassing the average EBIT of Rs. 3.08 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions